Table 3.

The association of TNFR2 and hsCRP with the annual change in mGFR and eGFR in linear mixed regression models

Dependent Variable and Risk FactorModel 1 UnadjustedModel 2 Adjusted for Baseline CovariatesaModel 3 Adjusted for Time-Dependent Covariatesa
Estimate (ml/min per 1.73 m2 per yr)95% CIP ValueEstimate (ml/min per 1.73 m2 per yr)95% CIP ValueEstimate (ml/min per 1.73 m2 per yr)95% CIP Value
TNFR2b
mGFR0.05−0.04 to 0.140.240.090.01 to 0.180.040.110.02 to 0.190.02
eGFRcre0.03−0.03 to 0.090.270.04−0.02 to 0.100.190.04−0.02 to 0.990.17
eGFRcys0.04−0.03 to 0.120.260.07−0.01 to 0.140.070.05−0.02 to 0.130.14
eGFRcrecys0.080.01 to 0.140.020.090.02 to 0.160.010.080.02 to 0.150.01
hsCRP
mGFR−0.03−0.05 to −0.02<0.001−0.03−0.05 to −0.010.001−0.03−0.05 to –0.010.001
eGFRcre−0.02−0.03 to −0.01<0.001−0.02−0.03 to −0.01<0.001−0.02−0.03 to −0.010.001
eGFRcys0.01−0.01 to 0.020.460.01−0.01 to 0.020.270.01−0.01 to 0.020.32
eGFRcrecys−0.01−0.02 to 0.010.38−0.01−0.02 to 0.010.45−0.01−0.02 to 0.010.42
• The Renal Iohexol-Clearance Survey Follow-Up Study. The estimates represent the interaction between time and 1 SD higher TNFR2 and 1 mg/L higher hsCRP on the annual change in mGFR/eGFR. A positive estimate represents a slower decline. Each row represents a separate linear mixed model with the different mGFR/eGFR as dependent variable. TNFR2, soluble TNF receptor 2; hsCRP, high-sensitivity C-reactive protein; mGFR, measured GFR; 95% CI, 95% confidence interval; eGFRcre, eGFR on the basis of creatinine; eGFRcys, eGFR on the basis of cystatin C; eGFRcrecys, eGFR on the basis of creatinine and cystatin C.

• a Adjusted for sex; weight; height; systolic BP; LDL cholesterol; HDL cholesterol; fasting triglycerides; hemoglobin A1c; urinary albumin-to-creatinine; number of cigarettes currently smoked; the use of angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs; and a dichotomous variable for the weekly use of alcohol.

• b The SD for TNFR2 is 651.5.